

Charity registration number 1188298

Company registration number 11785842 (England and Wales)

SUCCESS LIFE AFTER CURE LIMITED
ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

SUCCESS LIFE AFTER CURE LIMITED

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees	Philip Austin Jane Hobson Hugh Stewart Jennifer Limond Marco Previero Dr Helen Spoudeas Dr Jane Williams (Appointed 13 September 2023)
Charity number	1188298
Company number	11785842
Registered office	280 Bishopsgate London EC2M 4RB
Independent examiner	Tom Wilcox Counterculture Partnership LLP Unit 115, Ducie House Ducie Street Manchester M1 2JW

SUCCESS LIFE AFTER CURE LIMITED

CONTENTS

	Page
Chair's Report	1 - 3
Directors report	4 - 15
Independent examiner's report	16
Statement of financial activities	17
Balance sheet	18
Notes to the financial statements	19 - 26

SUCCESS LIFE AFTER CURE LIMITED

CHAIR'S REPORT

FOR THE YEAR ENDED 31 DECEMBER 2023

Chair's report - Cure Alone Is Not Enough

The Directors have pleasure in presenting their report and the financial statements for the charitable company for the year ended 31 December 2023. The Directors have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102) (effective 1 January 2019).

Chair's report - Cure Alone Is Not Enough

Another year has gone by, and SUCCESS continues to make progress in a difficult economic environment for the Charity sector.

Cure Alone Is Not Enough

Here at SUCCESS, we believe that curing children from brain tumours or brain cancers simply isn't enough. It's not enough to just give them back a life. It is incumbent on the health service to also restore their full health, maturational and intellectual potential. This is especially important now that 80% are deemed cured and live long lives. We estimate there are over 30,000 such survivors across the UK who need our advocacy and help. This is what we mean when we say, "**Cure Alone is Not Enough.**"

- **Cure alone is not enough** when one considers survival costs, in terms of current and future lived experience, health and mental well-being, independence and employment potential.
- **Cure alone is not enough** when one considers that it is the youngest children who have the longest time in which to mature (and hence accrue developmental gaps) until brain development completes at 25 years of age approximately.
- **Cure alone is not enough** when, although they need that rehabilitative support from diagnosis and will most benefit from it, they are least likely to get it.
- **Cure alone is not enough** when targeted educational and psychological support is a particular issue that parents tell us they struggle to access, especially for an innately gifted child.
- **Cure alone is not enough** if we allow them to fall intellectually to below the 2nd centile before they get their specific needs recognised.
- **Cure alone is not enough** if secondary life-threatening conditions such as hormone deficiencies, can be prevented or supported from tumour diagnosis by commissioning appropriate pituitary and endocrine specialists.
- **Cure alone is not enough** if children with rare very high survival [>90-95%] midbrain tumours are not accessing the highly specialised surgical and medical pituitary care we know will reduce collateral brain injury as do adults.
- And finally, **cure alone** - as is currently measured from 5y survival – is not enough as a statistical measure of outcomes. We need to measure secondary health-related quality of survival.

Redressing the balance – delivering on our vision

Whilst investment in cancer research and intensified treatments have translated into a 5-year cure for 80% of children with a brain tumour, this heavy price of 'cure' on the developing child is often overlooked.

Our long-term ambition to enable better futures for survivors of childhood cancer remains unchanged. Closely linked to this vision is the need to rationalise and improve both diagnostic treatment pathways for specific sub cohorts of very rare tumour and individualised rehabilitative services for all children. These require different specialist expertise during and beyond treatment.

SUCCESS LIFE AFTER CURE LIMITED

CHAIR'S REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2023

In order to do this, SUCCESS continues to advocate for the urgent development of a SUCCESS National Recovery Pathway, preferably integrated within the NHS, running in parallel to the current treatment pathway, tailored to the location of the tumour and whether in the deep midbrain or peripheral, but present from diagnosis and integrated beyond cure and into adult transition for every childhood brain tumour.

Our vision and objectives

Lobbying for a new service in the NHS involves navigating the complexities of healthcare systems, coordinating with diverse professionals, including new non-oncology services, and managing limited resources. This demands time, planning, effective communication, and alignment with existing resources and importantly a multi-faceted and stepped approach; our plan, over the next five years is to deliver on our vision, to create transformational change in the way health care is delivered to improve secondary health outcomes by delivering across **6** key milestones. This means encompassing brain injury evaluation and recovery from the beginning now that the majority survive.

1. **2023/2024 - Preliminary Assessment:** Much work has been undertaken to establish an initial assessment of rehabilitation needs over the last 3 years. We were therefore delighted to collaborate with GOSH and to commission from October 2024 a 9-month gap-analysis study of service gaps against current best standard for survivors of brain tumours at set points during and after treatment, and to have patient and parent representatives feeding into the questionnaires devised. SUCCESS also opened preliminary discussions with Birmingham neuroncology services in November 2023
2. **2024/2025 - Refining and Rationalizing the model of care:** SUCCESS will continue to work in this area and seek further assessments and engagement both at GOSH and across other major regional centres in the north as well as with key decision-makers in NHSE and government. This will further our collective understanding of both the need, and the organisational commissioning possibilities, professionals and patient requirements and desired key health outcome data across several stakeholders including patients, healthcare providers, and specialists, and set measurable goals for a national integrated diagnostic and rehabilitative pathway that is cost-efficient, safe and effective and which demonstrates quality improvement
3. **2025 - Achieve designated centres:** with designated standards and integrated care pathways for bespoke paediatric pituitary centres of expertise with highly specialised commissioning [HSCT] and CEO of NHSE to Implement new nationally endorsed CCLG guidelines for a sub cohort of very rare pituitary tumours affecting <100 CYP p.a.
4. **2025 SUCCESS Advocate Implementation:** initiate the integration of the enhanced diagnostic and new rehabilitative/recovery pathway with a focus on training and recruiting one or two SUCCESS nurse, psychology or OT advocates [case managers] in two key centres [north and south] which include a centralised bespoke pituitary sub cohort, to coordinate and facilitate specialized and individualised interventions and integrated care plans across the age span, progressively build on foundational elements for broader integration.
5. **2026/2027 - Focussed Multi-Disciplinary Collaboration Pilot:** broaden the scope of support in those centres to include all elements of augmented diagnostic assessment and decision-making by tumour location and the integrated rehabilitative therapies identified by initial needs assessments in Year 1 and 2. Ensure quality of survival secondary health outcome data are captured to demonstrate quality improvement and NHS efficiency savings

2028 - Expand Integration Across All Major Paediatric Centres: Gradually expand integration to include all major paediatric neuroncology centres in the UK and their adult transition counterparts, coordinate the management of standardized best practice integrated care pathways and capture parallel secondary health outcomes to oversee the implementation of a long-term, cohesive and unified approach to patient care.

SUCCESS LIFE AFTER CURE LIMITED

CHAIR'S REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2023

In order to deliver on this ambitious goal, we have worked holistically across several key objectives closely linked to the development of our long-term vision:

1. **Amplify the voice of survivors and their families:** by advocating for better characterisation of, and interventional remediation for, the collective unrecognised and unmet holistic rehabilitative needs of this vulnerable group. We have made good progress in this area by securing the support of several Parliamentarians and Peers, as well as key influencers within professional services linked to brain tumour rehabilitation. I have further led three publications in high impact peer – reviewed international journals [Lancet and Nature] on best practice for a 'trio' of rare pituitary tumours [first worldwide] affecting fewer than 100 children and young people in the UK every year, for whose equitable implementation we will continue to advocate for children as in adults.
2. **Reducing social isolation for survivors and their families:** by creating self-supporting communities and informal and formal peer networks and forums to enable friendships and significant relationships and improve mental health and employment outcomes. Much of our activities are focused in this critical area of the charity and we have delivered real value for a wider national community through our weekly virtual support group, WhatsApp survivor community and magazine, our two conferences in London and Birmingham and our London summer picnic and Christmas carol concert linked to fundraising events.
3. **Being a catalyst for rehabilitative services:** by bettering access to, and increasing investment in, holistic (neuroendocrine) rehabilitation and health research interventions. 2023 proved pivotal in this area. We established our current questionnaire study in collaboration with GOSH on gaps in service for survivors at 1-2 years post-diagnosis and 5-6 years post treatment, as against best practice standards. Additionally, our annual London Spring conference and, this year, our first regional Autumn roadshow, continue to serve as powerful advocacy platforms showcasing the needs of survivors, by the survivors themselves and a wider group of rehabilitative professionals, to important stakeholder groups such as neurooncology and community professionals, policy-makers, major donors, and survivors and their families. They also provide a growing and much needed educational role in this new area of chronic care and 'survivorship'.

A pivotal year for SUCCESS

So much has been achieved in 2023, so much more remains to be done - but 2023 feels like a pivotal year for the Charity allowing us to set our sights on delivering our vision.

Progress continues to be urgently needed in all areas relating to augmented diagnostic assessments and bespoke pituitary services, better diagnostic rehabilitative support, and to facilitate and develop an individualised and integrated recovery pathway from diagnosis. After years of neglect, it has become clear to me that in SUCCESS, this cause has finally found a voice and a hearing.

I am grateful to all our many parent, lay and professional volunteers, our donors, big and small, our board of trustees and patron, and to all the different medical professionals and Parliamentarians, who have contributed much appreciated support and informal advice over the last year.

In particular I extend my debt of gratitude to the cohort of courageous survivors and their families from whom we learn and for whom we exist and who never cease to inspire us.

Dr Helen Spoudeas

Chair

Date:


SUCCESS LIFE AFTER CURE LIMITED

DIRECTORS REPORT (INCLUDING DIRECTORS' REPORT)

FOR THE YEAR ENDED 31 DECEMBER 2023

Objectives and activities

Success Charity - Life After Cure exists to enable brighter futures for childhood brain tumour survivors.

To promote and protect the physical and mental health, and relieve the needs of childhood brain tumour survivors ("survivors") treated in the United Kingdom by providing equipment, facilities and services not normally provided by the statutory authorities and in particular:

- i. providing information, resources, advocacy support and education support to the survivors, their families and their education professionals;
- ii. providing multi-disciplinary clinician led rehabilitation treatment ancillary to that provided by the statutory authorities;
- iii. undertaking research into the treatment and outcomes of survivors to identify rehabilitation needs and challenges and publishing the useful results;
- iv. providing mentoring and network groups for survivors and their families; and
- v. providing grants to survivors to access medical support.

The Charity aims to achieve these objectives through a number of activities associated with its three driving ambitions of:

1. Amplifying the voice of survivors and their families
2. Reducing social isolation for survivors and their families
3. Being a catalyst for rehabilitative services

The Trustees have considered the Charity Commission's guidance on public benefit, including the guidance "public benefit: running a charity (PB2)" and are satisfied that the aims of the Charity are carried out wholly in pursuit of its charitable aims for the public benefit.

Significant activities

In the past year, SUCCESS has achieved several significant milestones, marking a transformative period for the charity.

SUCCESS has invested in furthering its relationship with strategic consultants Wareing Stewart, recognizing the need to enhance our fundraising and communication efforts. This partnership enabled the charity to secure £20,000 towards staffing from the National Lottery and thus to continue its focus on delivering key projects. It is currently working to build on this win in 2024 across several Grant giving organisations and for a portfolio of projects. This collaboration has not only amplified our national reach but has also enhanced donor engagement, laying the foundation for sustained, long-term support.

Our community engagement programme grew considerably in 2023, with the assistance of Wareing Stewart; it was encouraging to see our beneficiaries and their families come together over the summer to engage and raise funds for the charity through various activities.

SUCCESS LIFE AFTER CURE LIMITED

DIRECTORS REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

We have continued to secure the support of several Peers who are set to become influential allies in lobbying for our cause at a national level as well as the respected parliamentary and legal voice of our patron. Their backing has elevated our advocacy efforts, building on our credibility and influence in this space.

Our Annual London conference [our 6TH] remains our flagship national event as part of our conference programme, and we added a regional roadshow this year, which we plan to expand and develop in 2024 and beyond.

We have maintained our focus and investment in the Bravehearts magazine, launched in 2022 and written by and for survivors. The magazine features contributions from survivors and interviews with our Founder – Dr Helen Spoudeas, and showcases the voices, experiences, images, poetry and art of the survivors themselves.

Finally, we were delighted to secure the support of the Ronson Foundation granting £15,000 towards a collaborative study with GOSH in which our beneficiaries contributed, which is a pivotal service gap project, and a key first step towards raising awareness of the urgent need for transformational health care change and our long-term vision of enabling brighter futures for childhood brain tumour survivors.

Achievements against objectives

Reducing Social Isolation for Survivors and their Families.

SUCCESS strives to develop self-supporting communities and informal and formal peer networks and forums, recognising specific cultural and social differences, to enable friendships and significant relationships and improve mental health and employment outcomes.

This year, it has addressed this key objective as follows:

Conference programme

Our Annual London Spring Conference (March 2023)

Our Annual London Spring Conference (March 2023) was the first in person national conference for almost 3 years [after Covid], and brought together 140 survivors, their families, and a diverse group of professionals supporting the brain tumour survivor community throughout the cure and post-cure journey at the prestigious Royal College of Physicians Regents Park venue.

The conference itself is always focused on empowering survivors to share their stories and showcased their ability to harness professional understanding of service gaps and need for change. As part of the day, participants were able to engage in survivor-led creative workshops, demonstrating their talents, providing peer to peer support and a 'healing' space. This connected them not only with other survivors and families to form lasting friendships, but also with Success's growing platform of peer-to-peer opportunities, and therapeutic bursary programmes.

The conference brought together not just survivors and their families, but also professionals and, for the first time, politicians. It provided education and empowerment through medical and legal update talks and meet the expert sessions. This enabled us to increase our educational webinar library for beneficiaries further afield and harder to reach.

Participants shared a common belief, and one of the charity's core aim: that everyone diagnosed with a brain tumour during their first 25 developmental years deserves lifelong support to achieve their potential, to live the lives they choose, to be employed and live independently for the whole of the rest of their lives.

SUCCESS LIFE AFTER CURE LIMITED

DIRECTORS REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

This requires a unified voice and our drive as a charity is to facilitate this and develop a **National SUCCESS Recovery Pathway** to set a commissioning standard. It was particularly pleasing to see that **89% of participants**, when asked, understand why a parallel recovery pathway, tailored by tumour location in the periphery or deep midbrain, is essential.

Conference in numbers:

- 140 participants including survivors, parents, carers, professionals and political representatives.
- 10 Experts at everyone's disposal in "meet the experts" roadshow
- 6 survivors sharing their stories on stage
- 4 sessions on practical tips for accessing education and employment
- 4 survivor-led workshops focusing on creativity
- 1 panel discussion on achieving the SUCCESS recovery pathway for complete cure
- 1 Marketplace to introduce SUCCESS and its programmes, network, meet and share stories with other survivors and their families.

Feedback was captured following the conference. When asked what participants gained from attending it, the top three answers were:

- **Better lives:** inspiration and hope for the future;
- **Greater clarity:** and greater visibility of some of the issues facing survivors
- **Brain injury:** a better appreciation that brain tumours are brain injuries requiring their own rehabilitation, alongside treatment

For a full and **comprehensive feedback on our conference, please see QR code below.**

2024 Conference

The 2024 Success annual conference was held at 1 Wimple Street in London on the 2nd of March 2024. The theme for 2024 was "successful destinations" and we look forward to sharing achievements from this conference as part of next year's Annual Report.

Autumn Roadshow

The London conference itself, the positive feedback obtained and the need to reach more distant beneficiaries following the event, led directly to initiating a new satellite autumn roadshow conference of similar format in Birmingham (October 2023). This in turn led to focussed discussions and a follow-up local action plan with SUCCESS to support enhancement of the existing survivorship clinic with additional neurorehabilitation consultant sessions to be developed with Birmingham Children's hospital charity in 2024.

The regional roadshow programme continued to focus on the post-cure experience of brain tumour patients treated at this large centre in Birmingham and shared with their treating professionals. This first roadshow welcomed over 70 participants including survivors, siblings, parents, carers and professionals.

SUCCESS LIFE AFTER CURE LIMITED

DIRECTORS REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

The key outcome from the day was building lasting relationships with the clinical teams in Birmingham, alerting neurooncology professionals to stark unaddressed patient needs beyond cure, along with introducing new survivors to our community. Topics covered a broad spectrum from inspirational survivors' stories to hearing the experts on subjects ranging from Neurorehabilitation to diet and nutrition, a round table discussion on the proposed SUCCESS recovery pathway and an opportunity for questions and answers.

We also had the opportunity to gather feedback at the end of the day and were pleased that participants felt positive about several aspects of the roadshow. When asked through our online poll:

- 100% agreed that cure alone was not enough
- 83% agreed that Local Education Authorities should prioritise children and young people's return to school and organise for them to see an education psychologist
- 100% agreed no child with a brain tumour should receive oncology treatment without a complex neuro-psychological and health care assessment from diagnosis

Our Voices of SUCCESS programme

SUCCESS has actively engaged with its beneficiaries across a range of activities in 2023, to promote the sharing of information and advice for life during and beyond treatment, telling survivors' stories from their lived experience as survivors or siblings, and sharing the work of SUCCESS's wonderful contributors (known as 'Brave Hearts'). This included:

Braveheart Magazine

SUCCESS's quarterly online 'Braveheart' magazine - by survivors for survivors – regularly featuring a survivor story, survivors' articles on achievements and ambitions, survivors quiz, Q&A interviews with a professional or 'celebrity', updates on survivor group meetings, peer to peer experiences, calls for contributions and showcasing art and craft made by survivors.

Issue 5, with an increasing 'opt-in' circulation, was printed at Christmas as part of SUCCESS's Christmas Carol fundraising event to disseminate powerful messages of hope to patients, professionals and donors.

Our growing "unfocused"- focus group

This is a safe weekly Wednesday hour for approx. 7-10 survivors to meet online with Elaine, the Charity Administrator, and Helen Spoudeas and sent out to some 50 expressing interest. The focus group runs:

- as a means of welcoming new beneficiaries from across the UK, with at least 4 new active participants this year from Wales, Wye Valley, Derby;
- as a support and brain storming group;
- to share ideas about conferences, events and inspirational guests – e.g. Ryan Penniston
- to gain speakers and advocates and encourage organisational leaders /ambassadors
- to discuss how to improve quality of life within this community

Mediated WhatsApp Group

SUCCESS launched a mediated voluntary WhatsApp group in 2023, following interest by a growing community of survivors aged 16+ as a safe platform to share experiences, news, successes, anxieties, field questions, make contact with each other and provide support. The group has grown into a community of 40+ participants who are mutually supportive and get to make friendships they build on at conferences and networking events.

SUCCESS LIFE AFTER CURE LIMITED

DIRECTORS REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Ongoing engagements by survivors

Our survivor speaker contributions, which are key to all our public-facing events, include participation at our conferences (see section on conference as part of this Annual Report) and our annual Christmas Concert Fund Raising Event (our "light In The Shadow" appeal), where 6 survivors shared their hopes and fears in front of 230 carol concert guests and celebrated their achievements to inspire others on their journey to better lives.

Online community engagement

In 2023 SUCCESS began to consider developing a Survivor dedicated webpage, to be made up of survivors' blogs and a growing social media and communication strategy. This is still in its infancy and will be expanded in 2024 alongside dedicated pages for professionals and supporters

Peer to Peer Programme

Peer support continues to be a central tenet of the charity's offer for survivors. Other young people who have a shared lived experience of surviving a brain tumour are, with appropriate training and supervision, well placed to provide support for others going through a similar experience, earlier in that journey.

For background, a more formal service, training survivors to gain the skills to become Peer Mentors, planned in 2020, started in 2021 with an initial pilot scheme. Our partner in this area, Young People Matter, ran an accredited training course in Effective Mentoring Skills. Seven survivors older than 18 years of age, out of eight who applied, achieved a recognised qualification, and also gained confidence and valuable work/life experiences and skills, enhancing their self-esteem and employability.

Despite this initial positive engagement only 3 trained mentors subsequently supported mentees. Problems faced were due to 16+ age limitation of mentees, time availability of mentors, the need for appropriate interviews allocation and supervisory support and lack of subsequent ongoing funding to continue the rolling programme of training and recruiting.

This is an area that needs reviving and at the 2023 conference a new recruitment video was shown, and a decision made to train new mentors, and evaluate the programme by feedback from both mentees from as young as 13+, and mentors from 16+. Interviews to pair mentors with mentees were held in June 2023 and as a special parental request, two 13-year-olds were also introduced as 'friends.' As such, SUCCESS will realign fundraising efforts towards this initiative in 2024 with a view to re-launching Peer support as a key deliverable and priority project for the charity.

Being a Catalyst for Innovation and Rehabilitative Services for Survivors

SUCCESS aims to facilitate and develop better access to, and increasing investment in, holistic (neuroendocrine) rehabilitation and health research interventions targeted at improving existing services, identifying new ones and facilitating better community health and educational access. This year, it has progressed this area through two major projects.

Study project in partnership with GOSH

SUCCESS is delighted to be funding this project reviewing the provision and user experience of rehabilitation services following the diagnosis of a childhood brain tumour. which it developed in partnership with and neurooncology survivorship professionals at GOSH and the North Thames Paediatric Cancer Network [ODN]

This collaboration, debated with GOSH neuro-oncology since 2020, saw the formation of a successful working group engaged in 2022 to consider the SUCCESS Recovery Pathway, a study principle approved by London Cancer ODN in December 2022. The project was defined by SUCCESS with Professor Darren Hargrave and GOSH professionals in July 2023 and an 'in-house' part time Project lead identified. The formal study started in October 2023. The project is both. In alignment with the charity's overarching goals of providing brighter futures for survivors of childhood brain tumours and testament to the recognition that more needs to be done to improve their quality of life during and after treatment

SUCCESS LIFE AFTER CURE LIMITED

DIRECTORS REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

The aim of the project is to develop a patient-informed questionnaire survey of recovery service provision against best practice standards defined since 2005 NICE Children and Young People's Cancer Guidance and conduct a retrospective service review at two time points 1-2 and 5-6 years prior, led by a Specialist Physiotherapist in Paediatric Neuro-Oncology at GOSH supervised by Professor Hargrave. This started in November 2023 and is expected to be completed in August 2024.

The involvement of SUCCESS professionals and its's beneficiaries in devising the gap-analysis study as well as the questionnaires ensures the standards for comparison includes the rehabilitation services SUCCESS is proposing for consideration as the SUCCESS Survivorship Standard [SSS] of care which might be endorsed nationally – Phase 2 of this initiative.

The expected outcomes include:

- a review of access to and provision of rehabilitation services not only at 5y post cure [traditional 'late effects' monitoring] but also within the first year or two of diagnosis and treatment starting
- a detailed summary of views of patients and their carers on the provision of rehabilitation and the disciplines seen as being necessary
- feedback from therapists on the provision of rehabilitation services at different stages against long recommended standards of best practice
- insights and recommendations for phase 2 - formulating and enhancing individualised and integrated rehabilitation provision towards professional endorsement of the 'TRIPLE S' success survivorship standard

Telerehabilitation Bursary Programme with our Partner ReAbility UK

SUCCESS have teamed up with ReAbility Online UK to provide affordable, accessible, daily remote neuro-therapy sessions that are individualised and supervised (weekly) and delivered by a novel and highly sophisticated, games-based, cognimotion platform. The platform was developed at the leading Gertner Institute Israel where it has been widely adopted for adult neurorehabilitation, and also in Austria. It is not available in the UK and SUCCESS will be the gateway to its national use and evaluation in children with brain tumours.

After a successful pilot feasibility study in 2020, whose outcomes were presented and well received at a national meeting of the British Paediatric Neurology Association [BPNA] interest group for acquired brain injury [ABI] SUCCESS remained committed to raising funds for the second phase of the project, assist with the national recruitment of patients and commit to developing, rolling out and continuously evaluating the efficacy of the programme year on year, including integration of the model in SUCCESS's recovery pathway (separate proposal for supporting dedicated NHS centres).

The project stalled in late 2021 due to difficulties in raising the high costs needed for specialist insurance cover for this novel UK platform. The programme protocol was redeveloped over summer 2023 and the project group and partnership with ReAbility UK was re-instated in September 2023, with lead trustees Jenny Limond and Jane Hobbs heading the effort. Additionally, SUCCESS was able to secure funding to employ a project management resource to dedicate some time to the implementation and evaluation of this programme.

SUCCESS goal's is to prioritise the raising of funds specifically for this project with a view to start the first 12-weekly phase of recruitment of survivors in April 2024.

SUCCESS LIFE AFTER CURE LIMITED

DIRECTORS REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Achievements and performance

Significant activities and achievements against objectives

Amplify the Voice of Survivors and their Families

SUCCESS aspires to be the voice of survivors and their families by advocating for, and better understanding, their individual and collective unrecognised and unmet needs, with emphasis on 'hard to reach' and culturally or socially disadvantaged groups.

SUCCESS's lobbying and advocacy programme includes three strands.

Parliamentary advisory group

A Parliamentary Advisory Group led by Lord Guy Sandhurst, a retired medicolegal negligence barrister and me since 2022, taking advice from SUCCESS parents and cross-party peers Lords Stewart Wood and Sharpe, Derek Thomas MP, chair of the APPG on Brain Tumours, and our Patron and former attorney-general Dominic Grieve KC. The primary objective of this group is to advocate for the best interests of the charity's beneficiaries (past, present and future) and ensuring their representation at national parliamentary and NHSE level.

Medical Advisory Group

This will be a new initiative agreed in late 2023, with planned implementation during the first quarter of 2024. The Medical Advisory Group proposed will be led by our new trustee and neurorehabilitation specialist, Jane Williams with Jenny Limond as deputy, and will consist of key individuals with experience of NHSE commissioning and health service research for quality improvement to ensure equity of service provision in children and young people when evaluating projects with a medical component.

Their remit will be to ensure alignment with the charity's broader objectives of improving and driving transformational change across a broad spectrum of services.

"CHANGE" working party

A "CHANGE" working party will be created in 2024 after the annual conference. It will be involved in Standard Setting and Effecting Transformation by ensuring implementation of a 'trio' of National Multisociety and RCPCH-Endorsed Consensus Guidelines that set new standards for commissioning bespoke equitable services for CYP with rare Midbrain and Pituitary Tumours, in advising on the development and endorsement of the Success Survivorship Standard for a Mult Professional Recovery Pathway and I debating and providing update progress reports towards effecting transformational change at each SUCCESS Conference.

These endeavours are currently unfunded and voluntary contributions from interested experts. Nevertheless, they are a powerful voice which can be harnessed at our conferences, donor and fundraising events and for which we need to budget, in order to grow the endeavour and succeed.

Contribution made by volunteers

In the absence of a large charitable endowment at its start-up, much of the Charity's activity, is necessarily still carried out by volunteers, with our first p/t employee only starting in September 2021. As well as the Board of Trustees, other volunteers have given time and expertise with matters such as organising events, producing educational and information resources and providing support and legal advice. The charity has utilised consultants to assist with the operations, web-site development, marketing and communications, fundraising and governance although it is looking at integrating these capabilities by investing in additional in-house roles in 2024. A volunteer application process and role descriptions have been developed.

SUCCESS LIFE AFTER CURE LIMITED

DIRECTORS REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Performance of fundraising activities against objectives set

Sector challenges

The charity sector continues to face challenges, navigating through complexities arising post-COVID-19. Traditional fundraising methods have been disrupted shifting donor priorities and making fundraising more difficult. SUCCESS has worked hard to confront these challenges head-on, recognizing the importance of adapting to the new normal and has continued its investment partnering with a strategic fundraising consultant.

This investment is beginning to yield positive results, positioning SUCCESS for further growth in the coming year. In particular, we were pleased to secure a staffing grant of £20,000 in December 2023 from The National Lottery Community Fund to help the charity focus on delivering key projects for its community in 2024, and £5,000 from the Albert Hunt Trust to contribute towards SUCCESS's tele rehabilitation project set to re-launch in 2024.

Enhancing visibility

One of the Charity's key strategies to counter the challenges faced by the sector has been to enhance its visibility through a variety of events. These events not only provided platforms for fundraising but also strengthened our connection with the community. They included:

- **SUCCESS Annual June Picnic and Summer of Fun Raising:** This was our very first SUCCESS picnic and we were delighted at the uptake from our beneficiaries and select supporters who brought their own picnic to join us in Regents Park or held their own BBQ's and raised funds for us. This activity proved enormously fruitful in terms of networking, generating goodwill and also raising general funds from our own beneficiary supporters totalling approximately £20,000.

SUCCESS Carol Concert: this has turned into one of our major fundraising events in SUCCESS's calendar, taking place annually with the prestigious Norfolk Cathedral Choir and our patron, in different historic, City of London Churches. It creates a sense of community and solidarity, brings the survivor voice to a wider donor audience, whilst reinforcing the importance of supporting our cause during challenging times. This year, SUCCESS managed to raise just over £20k by welcoming over 230 guests. As in previous years, we are grateful to Gino Palmieri of GPIM for his company's contributing of £7,500 for the choir, venue and production costs, whilst the additional income was generated through ticket sales, raffle prizes and donations to our Light in the Shadows Appeal.

A post-event VIP reception for 50, catered and served by the trustees in the magnificent atrium of Temple Church, was also held this year, attracting key donors, with support from our Patron, Dominic Grieve and our Parliamentary lobbying group including Lord and Lady Sandhurst.

SUCCESS has already booked a date for its December 2024 Carol Concert at St Stephen's Walbrook.

- **Annual SUCCESS conference:** whilst SUCCESS does not view this particular forum as a fundraising event as such, it still managed to attract just over £21,000 in sponsorship, £11,930 of the total coming from one of the Charity's long-term pharma supporters, Pfizer, as part of its Patient benefit Grant, with further contributions from Sandoz and Merck Pharmaceuticals. The charity is extremely grateful for their ongoing support.
- **Service Gap Analysis in partnership with GOSH:** SUCCESS is particularly proud of its collaboration with GOSH on this project, which attracted the Ronson Foundation's grant of £15,000 and an additional £5,000 contribution from SUCCESS's founder, Helen Spoudeas further reinforcing her commitment to this important area of focus. The Charity had additional restricted reserves of £4,100 which it is allocating against this project. This will cover the total £22,500 cost for the operational delivery of the study later in 2024.

Overall, SUCCESS managed to generate income amounting to £119k across all activities. We are enormously grateful to all our supporters and donors, large and small for this vital support which means so much to us our board and to our beneficiaries as we continue to develop.

SUCCESS LIFE AFTER CURE LIMITED

DIRECTORS REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Fundraising performance

Performance of fundraising activities against objectives set

Fundraising continues to be challenging in a post-COVID market environment, where Charities are competing for ever more selective donors and cancer research into cure still takes priority despite the 80% survival rate in this paediatric field. Nevertheless, Success managed to raise some funds and donations in the year.

SUCCESS held its annual Christmas Carol Concert in December 2022. This Carol Concert was in support of our Christmas Appeal ('Light in the Shadows' Appeal). The aim was to raise £27,000, in order to pay for half the costs of employing our very first Success Nurse (and seek match-funding for the other half), to be an advocate for the many young survivors. In time, Success would like specially trained SUCCESS nurses, of which this would be the first, to bridge the gap between a legacy rehabilitative pathway currently available, and a second parallel non-oncology specialist team at each major treatment centre -neurodevelopmentalists, endocrinologists, psychiatrists, psychologists, allied rehabilitation therapists, dieticians and educationalists – working in parallel and alongside them from tumour diagnosis.

The concert itself had an excellent turnout, including a pre-concert reception attended by key potential donors of Success, members of parliament and the house of Lords and other influencers. We were extremely grateful to the Norwich Cathedral Choir School and their choirmaster and parent of a survivor, Ashley Grote, for their generosity and much enjoyed and admired performance, as well as to the vicar and staff of the Church where it was held- St Stephen Walbrook in London and the neighbouring Walbrook Club which hosted the reception.

Together with the sale of Christmas cards, the carol concert managed to raise £27,500. After associated costs, the amount raised still falls short of the Charity's net target and we continue to seek further funds to reach the stated amount required. These are restricted funds in the accounts as at 31 December 2022.

As in previous years, the Charity was grateful to Gino Palmeri of GPIM who continues to be a key supporter of Success and part-sponsored the carol concert again this year- with a donation of £5,000. We are also thankful to The Belgravia Centre for their ongoing and continued support of our cause, donating £1,000 towards the costs of our Light in Shadow Appeal.

We are thankful to Merck Serono Limited for their donation of £5,820 to continue to improve Success' website and digital platforms. The website is now a key asset of the Charity through which it publishes all its news and updates for beneficiaries, their families and professionals. Additionally, Success' presence on Twitter continues to increase with the Charity making better use of this platform to communicate key events and updates.

Success was pleased to support *Walking on the Edge: Thoughts on life and parenting after childhood brain cancer*, a book written by one of the Charity's own Trustee (Marco Previero) with a foreword by Helen Spoudeas. The book was written in support of Success to raise awareness of late side effects experienced by many survivors following treatment of brain cancer, with a donation by Marco Previero of £6,000 to cover costs associated with the publication and exposure of the story. Mentions of Success charity included several national BBC radio stations, a front cover feature on The Times on Saturday, and other mentions on online magazines such Bookbrunch.

Dr Helen Spoudeas continues to personally support the charity with a substantial donation at the start of the financial year of £20,000 as clear demonstration of the commitment she has in the delivery of the charity's stated objectives.

These donations are very important to us as a new charity and we desperately need to raise more funds to continue to develop and deliver on our ongoing projects and future ambitious goals. We are enormously grateful to all our supporters and donors, large and small for this vital support which means so much to us and to our board, to continue to develop.

SUCCESS LIFE AFTER CURE LIMITED

DIRECTORS REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2023

Financial review

Overview

The charity sector continues to face ongoing challenges with economic uncertainty negatively impacting income generation from fundraising events and individual and corporate donations generally. There are optimistic signs that this is reversing over the coming 12 months as more individuals express their intent to increase donations rather than cease giving, driven by a growing awareness of needs and a desire to contribute to solutions. This cautious optimism is reflected in SUCCESS's results for the year.

SUCCESS's income has increased from £85,312 in 2022, to £117,355 in 2023, boosted at the end of the year by a grant of £20,000 from The National Lottery Community Fund. This reflects a more focused fundraising strategy which included for the first time cost-effective sponsored "fun raising" challenges by our beneficiaries and supporters themselves which also raised close to £20,000.

This is validation that our message appears to be beginning to be better understood generally and by our donors and future supporters. However, our traditional pharmaceutical supporters for our conferences were unable to provide as much support as in previous years and this has led to us considering how to make the conferences self-supporting in the future with professional CPD.

This increased in income generation required greater investment in fundraising efforts, including strategic consultancy and marketing activities leading to a deficit for the year of £11,300.

In 2023, SUCCESS committed £89,682 to charitable activities (69% of its total expenditure – against 67% last year), with 55% of this being attributable to the London Annual Conference. After the 2.5 years Covid break, this was the first and largest face to face conference (attracting 180 against the 300 the Charity had originally paid for) and generated a deficit of £27,403. As a result the decision was made to reduce the number to 150 the following year and find a more cost effective but equally prestigious venue with which to partner, given the clear benefits to our beneficiary base and the positive feedback we obtained from key professionals and decision makers at both venues about what the charity stands for and its plan of action for transforming health care services to children with brain tumours.

The Carol Concert fundraising event was delivered much more cost effectively this year by gifting and serving the post conference catering we and at a larger venue which attracted 280 guests. Costs amounted to £11,316 against £23,248 income from this winter appeal.

Included in prepayment and accrued income of £47,343 is £22,358 deposit for SUCCESS' 2024 Annual Conference and £20,000 accrued grant income awarded by The National Lottery Fund in December 2023 but received in 2024.

The charity's objectives and mission involve complex projects that necessitate collaboration and dedication from various healthcare stakeholders. To have an impact, these initiatives demand building "a head of steam" by sustained effort over time, thereby gradually transforming the charity into a positive force for advocacy and transformational change in the healthcare landscape. This year has certainly felt transformative in that sense, and the Board remains cautiously optimistic that investing in this way will reap long-term benefits for our beneficiary base including a growing educational digital library of professional talks, and training and empowering new non-oncology professionals who will care for this new niche cohort of patients.

Continuing from the previous year, a notable risk was the charity's limited capacity to generate sustainable revenue streams for its initiatives and the staffing salaries to support them. To address this, SUCCESS engaged a business consulting and fundraising firm last year, and whilst this cost represents 21% of the total in 2023, the Charity is beginning to see some positive results from a fundraising perspective with some £20,000 and £25,000 awarded from grants and our supporters directly attributable to this investment out of our total £122k. The expectation is that this proportion will continue to increase in 2024, despite a slow start to income generation in the first quarter of 2024.

The Board and Risk Committee continue to acknowledge that an urgent focus on fundraising is needed to deliver on the broader projects identified as part of its three-year plan.

SUCCESS LIFE AFTER CURE LIMITED

DIRECTORS REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Reserves policy

The Charity continues to monitor reserves on an ongoing basis, including at the last two Board Meetings to date on 9th February 2024 and 8th March 2024. SUCCESS is still in the growing phase, and the Board appreciates the need to balance reserves with sufficient fund allocation for progression of charitable activities as detailed in above.

Total unrestricted reserves carried forward stand at £102,896 for the year ended 31 December 2023 (a decline of approximately 15% on last year), with an additional £22,038 of restricted funds allocated to SUCCESS' GOSH gap analysis project and £5,000 restricted funds for ReAbility in 2024.

The Trustees continue to believe it would not be commercially meaningful to set a formulaic reserve policy but agree to monitor costs and revenues on a quarterly basis as part of its risk and control procedures. Additionally, current reserves cover at least six months of operational expenses, and at this stage, the Trustees feel this is a reasonable commercial buffer to maintain – and this is reviewed quarterly as part of our Board meetings.

Principal funding sources

The charity's principal sources of funds (including any fundraising)

The charity raises income through a combination of events, individual giving, corporate support and grants. Last year, the charity registered with Stripe and Just giving, and donations have been received through these methods. Credit card and PayPal donations can be made directly through the website.

Major risks

Risk Policy

The Risk Committee has conducted a review of the major risks to which the charity is exposed using the Charity Commission framework. SUCCESS's risk register has reviewed (it is updated at least annually by the Risk Committee and presented to the Board).

Where appropriate, systems or procedures have been established to mitigate the risks the charity faces. Internal control risks are minimised by the implementation of procedures for two levels of authorisation of all financial transactions.

The main risks identified remain similar to previous years:

- generating sustainable income in order to deliver services for its beneficiaries – SUCCESS believes it should continue to drive income generation and leverage on the investment it has made to date in a firm of fundraising business consultant; and
- operational delivery of projects - SUCCESS has allocated £20,000 annually for a project administrator role. An individual has been identified and has started with the charity in February 2024.

Risk Policy

The Board of Trustees has conducted a review of the major risks to which the charity is exposed using the Charity Commission framework. A risk register has been established and is reviewed and updated at least annually by the Board. A small working group has been formed to undertake this work, meeting more regularly and reporting directly to the Board for oversight. Where appropriate, systems or procedures have been established to mitigate the risks the charity faces. Internal control risks are minimised by the implementation of procedures for two levels of authorisation of all financial transactions.

The main risk identified is:

- a. generating sustainable income in order to deliver services for its beneficiaries.

This item was therefore given higher priority on the next Board agenda with the decision to recruit a full-time COO and engage a firm of fundraising business consultants to directly address and mitigate this risk.

SUCCESS LIFE AFTER CURE LIMITED

DIRECTORS REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Structure, governance and management

Governing document

Success is a charitable company limited by guarantee and established under its Memorandum and Articles of Association. In the event of the company being wound up every member of the charity undertakes to contribute such amount as may be required (not exceeding £1).

Trustee selection methods including details of any constitutional provisions:

The Board spent time reviewing the Charity Commission guidance, the Charity Governance Code and other governance reference material. Trustee role descriptions and a Code of Conduct were produced and implemented.

The trustees, who are also the directors for the purpose of company law, and who served during the year and up to the date of signature of the financial statements were:

Philip Austin

Jane Hobson

Hugh Stewart

Richard Crowther

(Resigned 9 February 2024)

Jennifer Limond

Marco Previero

Dr Helen Spoudeas

Dr Jane Williams

(Appointed 13 September 2023)

Recruitment and appointment of trustees


Trustee recruitment, selection and succession planning will be agreed as part of the ongoing governance of the organisation. This will include consideration of the requirements for a diverse board membership, ensuring that trustees have different backgrounds and experiences to enable better decisions.

A comprehensive programme of governance training was included in board meetings, to ensure that trustees were aware of the responsibilities and expectations of them, and to be able to review their effectiveness. Plans to ensure ongoing board development and training are in progress.

The charity is governed by the Board of Trustees, with advice and support from external freelance consultants, who operate as project managers for some aspects of charitable activity. A series of sub-groups and steering groups support the work of the Board and the operational delivery of charitable aims and objectives. External support is provided on a pro bono basis by a legal firm, as well as several volunteers.

The charity operates within the wider environment of brain tumour charities and services and has formed links with other charities and NHS services, through informal discussions, with the ultimate aim of enhancing the lives of brain tumour survivors.

The Directors report was approved by the Board of Trustees.



.....
Dr Helen Spoudeas

Director

Date: 14.08.2024

SUCCESS LIFE AFTER CURE LIMITED

INDEPENDENT EXAMINER'S REPORT

TO THE TRUSTEES OF SUCCESS LIFE AFTER CURE LIMITED

I report to the trustees on my examination of the financial statements of Success Life After Cure Limited (the charity) for the year ended 31 December 2023.

Responsibilities and basis of report

As the trustees of the charity (and also its directors for the purposes of company law) you are responsible for the preparation of the financial statements in accordance with the requirements of the Companies Act 2006 (the 2006 Act).

Having satisfied myself that the financial statements of the charity are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the charity's financial statements carried out under section 145 of the Charities Act 2011 (the 2011 Act). In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

- 1 accounting records were not kept in respect of the charity as required by section 386 of the 2006 Act; or
- 2 the financial statements do not accord with those records; or
- 3 the financial statements do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
- 4 the financial statements have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.



Tom Wilcox
Counterculture Partnership LLP
Unit 115, Ducie House
Ducie Street
Manchester
M1 2JW

Dated: 14 August 2024

SUCCESS LIFE AFTER CURE LIMITED

STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 DECEMBER 2023

		Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £	Unrestricted funds 2022 £	Restricted funds 2022 £	Total 2022 £
	Notes						
Income from:							
Donations and legacies	3	79,973	37,382	117,355	59,675	25,637	85,312
Total income		79,973	37,382	117,355	59,675	25,637	85,312
Expenditure on:							
Raising funds	4	11,079	4,374	15,453	3,789	945	4,734
Charitable activities	5	80,535	32,667	113,202	48,638	20,592	69,230
Total expenditure		91,614	37,041	128,655	52,427	21,537	73,964
Net income/(expenditure)		(11,641)	341	(11,300)	7,248	4,100	11,348
Transfers between funds							
		(10,836)	10,836	-	-	-	-
Net movement in funds		(22,477)	11,177	(11,300)	7,248	4,100	11,348
Reconciliation of funds:							
Fund balances at 1 January 2023		125,373	15,860	141,233	118,125	11,760	129,885
Fund balances at 31 December 2023		102,896	27,037	129,933	125,373	15,860	141,233

The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.

SUCCESS LIFE AFTER CURE LIMITED

BALANCE SHEET

AS AT 31 DECEMBER 2023

	Notes	2023 £	£	2022 £	£
Fixed assets					
Tangible assets	9		209		209
Current assets					
Debtors	10	48,785		58,410	
Cash at bank and in hand		94,950		96,196	
		143,735		154,606	
Creditors: amounts falling due within one year	11	(14,011)		(13,582)	
Net current assets			129,724		141,024
Total assets less current liabilities			129,933		141,233
Net assets			129,933		141,233
The funds of the charity					
Restricted income funds	12	27,037		15,860	
Unrestricted funds		102,896		125,373	
		129,933		141,233	

The company is entitled to the exemption from the audit requirement contained in section 477 of the Companies Act 2006, for the year ended 31 December 2023.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the trustees on 14.08.24



Marco Previero
Director

Company registration number 11785842 (England and Wales)

SUCCESS LIFE AFTER CURE LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2023

1 Accounting policies

Charity information

Success Life After Cure Limited is a private company limited by guarantee incorporated in England and Wales. The registered office is 280 Bishopsgate, London, EC2M 4RB.

1.1 Accounting convention

The financial statements have been prepared in accordance with the charity's [governing document], the Companies Act 2006, FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102") and the Charities SORP "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019). The charity is a Public Benefit Entity as defined by FRS 102.

The charity has taken advantage of the provisions in the SORP for charities not to prepare a Statement of Cash Flows.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives.

Restricted funds are subject to specific conditions by donors or grantors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

Endowment funds are subject to specific conditions by donors that the capital must be maintained by the charity.

1.4 Income

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

SUCCESS LIFE AFTER CURE LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2023

1 Accounting policies

(Continued)

1.5 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement, and the amount of the obligation can be measured reliably.

Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges are allocated on the portion of the asset's use.

1.6 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures and fittings	20% reducing balance basis
-----------------------	----------------------------

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the statement of financial activities.

1.7 Impairment of fixed assets

At each reporting end date, the charity reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

1.8 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.9 Financial instruments

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

SUCCESS LIFE AFTER CURE LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

1 Accounting policies

(Continued)

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

1.10 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3 Income from donations and legacies

	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £	Unrestricted funds 2022 £	Restricted funds 2022 £	Total 2022 £
Donations and gifts	79,973	37,382	117,355	59,675	25,637	85,312

SUCCESS LIFE AFTER CURE LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

4 Expenditure on raising funds

	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £	Unrestricted funds 2022 £	Restricted funds 2022 £	Total 2022 £
Fundraising and publicity						
Seeking donations, grants and legacies	11,079	4,374	15,453	3,789	945	4,734

SUCCESS LIFE AFTER CURE LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

5 Costs of charitable activities by fund type

	Unrestricted Funds 2023 £	Restricted Funds 2023 £	2023 £	2022 £
Amplify voice of survivors	6,559	-	6,559	40,808
Reduce solical isolation	41,303	19,317	60,620	6,700
Catalyst for post-cure recovery	53	13,350	13,403	2,242
Support costs	32,620	-	32,620	24,213
	<u>80,535</u>	<u>32,667</u>	<u>113,202</u>	<u>73,964</u>

Costs of charitable activity by activity type

	Undertaken directly £	Support costs £	2023 £	2022 £
Support costs				
Amplify voice of survivors	6,559	2,656	9,215	60,462
Reduce solical isolation	60,620	24,551	85,171	9,927
Catalyst for post-cure recovery	13,403	5,413	18,816	3,574
	<u>80,582</u>	<u>32,620</u>	<u>113,202</u>	<u>73,964</u>

Analysis of support costs

	Amplify voice £	Reduce isolation £	Catalyst post-cure £	2023 £	2022 £
Managment	1,387	12,818	2,826	17,031	16,258
General overheads	668	6,172	1,361	8,201	5,022
Website development	506	4,679	1,032	6,217	1,661
General Governance	95	882	194	1,171	1,172
	<u>2,656</u>	<u>24,551</u>	<u>5,413</u>	<u>32,620</u>	<u>24,213</u>

6 Trustees

None of the trustees (or any persons connected with them) received any remuneration or benefits from the charity during the year.

SUCCESS LIFE AFTER CURE LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

7 Employees

The average monthly number of employees during the year was:

2023 Number	2022 Number
1	1

There were no employees whose annual remuneration was more than £60,000.

8 Taxation

The charity is exempt from taxation on its activities because all its income is applied for charitable purposes.

9 Tangible fixed assets

	Fixtures and fittings £
Cost	
At 1 January 2023	209
At 31 December 2023	209
Carrying amount	
At 31 December 2023	209
At 31 December 2022	209

10 Debtors

	2023 £	2022 £
Amounts falling due within one year:		
Trade debtors	1,534	7,398
Other debtors	47,251	51,012
	48,785	58,410

11 Creditors: amounts falling due within one year

	2023 £	2022 £
Trade creditors	12,839	12,410
Accruals and deferred income	1,172	1,172
	14,011	13,582

SUCCESS LIFE AFTER CURE LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2023

12 Restricted funds

The restricted funds of the charity comprise the unexpended balances of donations and grants held on trust subject to specific conditions by donors as to how they may be used.

	At 1 January 2023	Incoming resources	Resources expended	Transfers	At 31 December 2023
	£	£	£	£	£
	-	-	-	-	-
Conference	11,760	11,930	(23,690)	-	-
Nurse Appeal	4,100	20,000	(2,063)	-	22,037
ReAbility	-	5,452	(11,288)	10,836	5,000
	<u>15,860</u>	<u>37,382</u>	<u>(37,041)</u>	<u>10,836</u>	<u>27,037</u>
	<u><u>15,860</u></u>	<u><u>37,382</u></u>	<u><u>(37,041)</u></u>	<u><u>10,836</u></u>	<u><u>27,037</u></u>
Previous year:	At 1 January 2022	Incoming resources	Resources expended	Transfers	At 31 December 2022
	£	£	£	£	£
Conference	11,760	-	-	-	11,760
Nurse Appeal	-	25,637	(21,537)	-	4,100
	<u>11,760</u>	<u>25,637</u>	<u>(21,537)</u>	<u>-</u>	<u>15,860</u>
	<u><u>11,760</u></u>	<u><u>25,637</u></u>	<u><u>(21,537)</u></u>	<u><u>-</u></u>	<u><u>15,860</u></u>

Note to the restricted funds

ReAbility is an online rehabilitative tool that helps people with neurological damage get better; and enables them to lead their very best lives. The Charity as a beneficiary of a grant for £5,000 received from The Albert Hunt Trust as contribution towards this project which is due to start in 2024.

MDT relates predominantly to a donation by H Spoudeas (£5,000) and grant by the Ronson Foundation (£20,000) has been used for the ongoing delivery of a project started in February 2024 reviewing the provision and user experience of rehabilitation services following the diagnosis of a childhood brain tumour. which the Charity has developed in partnership with and neuroncology survivorship professionals at GOSH and the North Thames Paediatric Cancer Network [ODN]. The project is due to complete in August 2024.

SUCCESS LIFE AFTER CURE LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2023

13 Unrestricted funds

The unrestricted funds of the charity comprise the unexpended balances of donations and grants which are not subject to specific conditions by donors and grantors as to how they may be used. These include designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes.

	At 1 January 2023	Incoming resources	Resources expended	Transfers	At 31 December 2023
	£	£	£	£	£
General funds	125,373	79,973	(91,614)	(10,836)	102,896
	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>
Previous year:	At 1 January 2022	Incoming resources	Resources expended	Transfers	At 31 December 2022
	£	£	£	£	£
General funds	118,125	59,675	(52,427)	-	125,373
	<u> </u>	<u> </u>	<u> </u>	<u> </u>	<u> </u>

14 Analysis of net assets between funds

	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £
At 31 December 2023:			
Tangible assets	209	-	209
Current assets/(liabilities)	102,687	27,037	129,724
	<u> </u>	<u> </u>	<u> </u>
	102,896	27,037	129,933
	<u> </u>	<u> </u>	<u> </u>
	Unrestricted funds 2022 £	Restricted funds 2022 £	Total 2022 £
At 31 December 2022:			
Tangible assets	209	-	209
Current assets/(liabilities)	125,164	15,860	141,024
	<u> </u>	<u> </u>	<u> </u>
	125,373	15,860	141,233
	<u> </u>	<u> </u>	<u> </u>